| Title: |
Peripheral Stem Cell Apheresis is Feasible Post (131)Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution |
| Authors: |
Kraal, Kathelijne C. J. M.; Timmerman, Ilse; Kansen, Hannah M.; van den Bos, Cor; Zsiros, Jozsef; van den Berg, Henk; Somers, Sebastiaan; Braakman, Eric; Peek, Annemarie M. L.; van Noesel, Max M.; van der Schoot, C. Ellen; Fiocco, Marta; Caron, Huib N.; Voermans, Carlijn; Tytgat, Godelieve A. M. |
| Source: |
Kraal, K C J M, Timmerman, I, Kansen, H M, van den Bos, C, Zsiros, J, van den Berg, H, Somers, S, Braakman, E, Peek, A M L, van Noesel, M M, van der Schoot, C E, Fiocco, M, Caron, H N, Voermans, C & Tytgat, G A M 2019, 'Peripheral Stem Cell Apheresis is Feasible Post (131)Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution', Clinical Cancer Research, vol. 25, no. 3, pp. 1012-1021. https://doi.org/10.1158/1078-0432.CCR-18-1904 |
| Publication Year: |
2019 |
| Collection: |
University of Groningen research database |
| Subject Terms: |
I-131-METAIODOBENZYLGUANIDINE I-131-MIBG THERAPY; CD34(+) CELLS; IODINE-131-METAIODOBENZYLGUANIDINE THERAPY; PHASE-I; METAIODOBENZYLGUANIDINE; ENGRAFTMENT; TOXICITY; RECOVERY; TRANSPLANTATION; CHEMOTHERAPY |
| Description: |
Purpose: Targeted radiotherapy with (131)iodine-metaiodobenzylguanidine (I-131-MIBG) is effective for neuroblastoma (NBL), although optimal scheduling during high-risk (HR) treatment is being investigated. We aimed to evaluate the feasibility of stem cell apheresis and study hematologic reconstitution after autologous stem cell transplantation (ASCT) in patients with HR-NBL treated with upfront I-131-MIBG-therapy. Experimental Design: In two prospective multicenter cohort studies, newly diagnosed patients with HR-NBL were treated with two courses of I-131-MIBG-therapy, followed by an HR-induction protocol. Hematopoietic stem and progenitor cell (e. g., CD34(+) cell) harvest yield, required number of apheresis sessions, and time to neutrophil (> 0.5 x 10(9)/L) and platelet (> 20 x 10(9)/L) reconstitution after ASCT were analyzed and compared with " chemotherapy-only"-treated patients. Moreover, harvested CD34(+) cells were functionally (viability and clonogenic capacity) and phenotypically (CD33, CD41, and CD62L) tested before cryopreservation (n = 44) and/or after thawing (n = 19). Results: Thirty-eight patients (47%) were treated with I-131-MIBG-therapy, 43 (53%) only with chemotherapy. Median cumulative I-131-MIBG dose/kg was 0.81 GBq (22.1 mCi). Median CD34(+) cell harvest yield and apheresis days were comparable in both groups. Post ASCT, neutrophil recovery was similar (11 days vs. 10 days), whereas platelet recovery was delayed in I-131-MIBG-compared with chemotherapy-only-treated patients (29 days vs. 15 days, P = 0.037). Testing of harvested CD34(+) cells revealed a reduced post-thaw viability in the I-131-MIBG-group. Moreover, the viable CD34(+) population contained fewer cells expressing CD62L (L-selectin), a marker associated with rapid platelet recovery. Conclusions: Harvesting of CD34(+) cells is feasible after I-131-MIBG. Platelet recovery after ASCT was delayed in I-131-MIBG-treated patients, possibly due to reinfusion of less viable and CD62L-expressing CD34(+) cells, but without clinical ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
1078-0432 |
| Relation: |
info:eu-repo/semantics/altIdentifier/wos/000457395900016; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/380237e7-bcac-4c71-a450-655c621f9129; info:eu-repo/semantics/altIdentifier/pissn/1078-0432 |
| DOI: |
10.1158/1078-0432.CCR-18-1904 |
| Availability: |
https://hdl.handle.net/11370/380237e7-bcac-4c71-a450-655c621f9129; https://research.rug.nl/en/publications/380237e7-bcac-4c71-a450-655c621f9129; https://doi.org/10.1158/1078-0432.CCR-18-1904; https://pure.rug.nl/ws/files/91677235/1012.full.pdf |
| Rights: |
info:eu-repo/semantics/openAccess ; https://www.rug.nl/library/open-access/article-25fa-pilot-end-user-agreement |
| Accession Number: |
edsbas.498FF57 |
| Database: |
BASE |